December 4, 2022

Medical Trend

Medical News and Medical Resources

Moderna: HIV Trimeric mRNA Vaccine Phase I Clinical Completed First Dosing

Moderna: HIV Trimeric mRNA Vaccine Phase I Clinical Completed First Dosing



 

Moderna: HIV Trimeric mRNA Vaccine Phase I Clinical Completed First Dosing.


On March 14, 2022 Moderna, Inc. announced the first recipient of its human immunodeficiency virus (HIV) trimeric mRNA vaccine (development code: mRNA-1574) in a Phase I clinical trial.

The subject has completed the drug administration.

 

“Developing a vaccine that induces sustained levels of protection against HIV neutralizing antibodies in humans has historically been elusive,” said Moderna President Stephen Hoge, MD . “At Moderna, we believe mRNA provides a new way to address this challenge.

With the launch of our second HIV vaccine trial, we are advancing our strategy to leverage multiple mRNA-encoded native HIV-like trimers and our mRNA platform to accelerate the development of protective HIV vaccines.”

 

Phase I trial HVTN 302

This open-label, multicenter, randomized phase I trial (HVTN 302) was designed to evaluate the safety and immunogenicity of the HIV trimeric mRNA vaccine mRNA-1574 . The trial is expected to enroll approximately 100 HIV-negative adults between the ages of 18 and 55.

The trial was funded by the Division of AIDS ( D AIDS ) of the National Institute of Allergy and Infectious Diseases ( NIAID) of the National Institutes of Health ( NIH) .

 

Moderna: HIV Trimeric mRNA Vaccine Phase I Clinical Completed First Dosing.

(NCT05217641 Screenshot from: clinicaltrials.gov)

 

“It’s great to see that mRNA, a key platform for COVID vaccines, is making its way into the HIV vaccine space,” said Larry Corey, PhD, Principal Investigator, HIV Vaccine Trials Network (HVTN) Operations Center . The field uses mRNA to pave the way. ”

 

 

Moderna in HIV

HIV is the virus that causes Acquired Immune Deficiency Syndrome (commonly known as “AIDS”, AIDS), a lifelong progressive disease with no effective cure. Currently, approximately 38 million people worldwide are infected with HIV.

 

Moderna is currently advancing two HIV preventive vaccine strategies based on germline targeting* and immune-focused approaches, in addition to mRNA-1574 described above , Moderna is also working on IAVI and Bill & Melinda Gates With the support of the foundation, the phase I clinical trials of HIV vaccine mRNA-1644 and mRNA-1644v2-core were carried out.

 

*In 2019, SCIENCE published a paper titled A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses, introducing an HIV vaccine that initiates induction of broadly neutralizing antibodies (bnAbs) through germ cell-targeted antigens Strategy.

 

 

Reference:
[1] www.modernatx.com
[2] Jon M. Steichen et al. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science, 2019, doi:10.1126/science.aax4380.

Moderna: HIV Trimeric mRNA Vaccine Phase I Clinical Completed First Dosing.

(source:internet, reference only)


Disclaimer of medicaltrend.org